BioCentury | Sep 6, 2019
Company News

Management tracks: Prometheus, Step, Spero, NorthSea, Aristea, MODAG and more

...Biosciences Inc. (San Diego, Calif.), formerly known as Precision IBD Inc. McKenna was president at Salix Pharmaceuticals Ltd....
BioCentury | Apr 25, 2019
Company News

Salix licenses S1P receptor modulator from Mitsubishi

...modulator in Salix, two years after Biogen decided to return its rights to the compound. Salix Pharmaceuticals Ltd....
...receives an undisclosed upfront payment, and is eligible for development and regulatory milestones, plus royalties. Salix...
...from University of California Los Angeles (see "Salix Licenses New NASH Target from UCLA" ). Salix...
BioCentury | Apr 1, 2019
Company News

Salix licenses new NASH target from UCLA

...with a license from UCLA to a compound against a new target in the space. Salix Pharmaceuticals Ltd....
...non-alcoholic steatohepatitis, non-alcoholic fatty liver disease and other gastrointestinal and liver diseases. The program is Salix's...
...showed that activating ADCYAP1R1 increased satiety and lean mass while suppressing appetite and fat accumulation. Salix...
BioCentury | Jan 5, 2019
Company News

Flurry of management moves on eve of JPM

...and general counsel, a newly created position. He was SVP, head of legal branded Rx (Salix...
BioCentury | Feb 16, 2018
Clinical News

FDA prolongs review of Valeant's bowel cleansing agent

...The Salix Pharmaceuticals Ltd. subsidiary of Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) and partner Norgine B.V. (Amsterdam, the...
...an NDA for Plenvu (NER1006) for bowel cleansing. The new PDUFA date is May 13. Salix...
BioCentury | Jun 16, 2017
Company News

GeneriCo wins IPR for Apriso

...TSX:VRX; NYSE:VRX). The IPR petition was filed by generics company GeneriCo LLC (St. Louis, Mo.). Salix Pharmaceuticals Ltd....
BioCentury | Jan 6, 2017
Finance

Good riddance

...NYSE:ABBV) acquired Pharmacyclics Inc. for $21 billion; and Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) acquired Salix Pharmaceuticals Ltd....
BioCentury | Nov 1, 2016
Company News

Valeant gains after Salix rumors

...to $23.86 on Tuesday after media reports said it was discussing a sale of its Salix...
...has held discussions about "various divestitures including but not limited to Salix." Since Valeant acquired Salix...
...its stock closed at $173.26 in New York (see BioCentury Extra, March 16, 2015) . Chris Lieu Salix Pharmaceuticals Ltd. Valeant...
BioCentury | Sep 12, 2016
Company News

Valeant Pharmaceuticals sales and marketing update

...mu opioid receptor (MOR; OPRM1 ) antagonist, excluding Japan, through its 2015 acquisition of Salix Pharmaceuticals Ltd. Salix...
BioCentury | Aug 22, 2016
Company News

Valeant Pharmaceuticals, Pharming deal

...4Q16. Pharming granted Santarus Inc. rights to the product in 2010. Santarus was acquired by Salix Pharmaceuticals Ltd....
Items per page:
1 - 10 of 633
BioCentury | Sep 6, 2019
Company News

Management tracks: Prometheus, Step, Spero, NorthSea, Aristea, MODAG and more

...Biosciences Inc. (San Diego, Calif.), formerly known as Precision IBD Inc. McKenna was president at Salix Pharmaceuticals Ltd....
BioCentury | Apr 25, 2019
Company News

Salix licenses S1P receptor modulator from Mitsubishi

...modulator in Salix, two years after Biogen decided to return its rights to the compound. Salix Pharmaceuticals Ltd....
...receives an undisclosed upfront payment, and is eligible for development and regulatory milestones, plus royalties. Salix...
...from University of California Los Angeles (see "Salix Licenses New NASH Target from UCLA" ). Salix...
BioCentury | Apr 1, 2019
Company News

Salix licenses new NASH target from UCLA

...with a license from UCLA to a compound against a new target in the space. Salix Pharmaceuticals Ltd....
...non-alcoholic steatohepatitis, non-alcoholic fatty liver disease and other gastrointestinal and liver diseases. The program is Salix's...
...showed that activating ADCYAP1R1 increased satiety and lean mass while suppressing appetite and fat accumulation. Salix...
BioCentury | Jan 5, 2019
Company News

Flurry of management moves on eve of JPM

...and general counsel, a newly created position. He was SVP, head of legal branded Rx (Salix...
BioCentury | Feb 16, 2018
Clinical News

FDA prolongs review of Valeant's bowel cleansing agent

...The Salix Pharmaceuticals Ltd. subsidiary of Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) and partner Norgine B.V. (Amsterdam, the...
...an NDA for Plenvu (NER1006) for bowel cleansing. The new PDUFA date is May 13. Salix...
BioCentury | Jun 16, 2017
Company News

GeneriCo wins IPR for Apriso

...TSX:VRX; NYSE:VRX). The IPR petition was filed by generics company GeneriCo LLC (St. Louis, Mo.). Salix Pharmaceuticals Ltd....
BioCentury | Jan 6, 2017
Finance

Good riddance

...NYSE:ABBV) acquired Pharmacyclics Inc. for $21 billion; and Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) acquired Salix Pharmaceuticals Ltd....
BioCentury | Nov 1, 2016
Company News

Valeant gains after Salix rumors

...to $23.86 on Tuesday after media reports said it was discussing a sale of its Salix...
...has held discussions about "various divestitures including but not limited to Salix." Since Valeant acquired Salix...
...its stock closed at $173.26 in New York (see BioCentury Extra, March 16, 2015) . Chris Lieu Salix Pharmaceuticals Ltd. Valeant...
BioCentury | Sep 12, 2016
Company News

Valeant Pharmaceuticals sales and marketing update

...mu opioid receptor (MOR; OPRM1 ) antagonist, excluding Japan, through its 2015 acquisition of Salix Pharmaceuticals Ltd. Salix...
BioCentury | Aug 22, 2016
Company News

Valeant Pharmaceuticals, Pharming deal

...4Q16. Pharming granted Santarus Inc. rights to the product in 2010. Santarus was acquired by Salix Pharmaceuticals Ltd....
Items per page:
1 - 10 of 633